Table 5 Prescription of adjuvant chemotherapy according to biological type and stage. Chi square test was significant (p < 0.0001) for each biological subtype
Stage | Luminal A | Luminal B | HER2 | Triple Negative | ||||
|---|---|---|---|---|---|---|---|---|
CT yes, N (%) | CT no, N (%) | CT yes, N (%) | CT no, N (%) | CT yes, N (%) | CT no, N (%) | CT yes, N (%) | CT no, N(%) | |
IA* | 12 (6.0%) | 187 (94.0%) | 10 (30.3%) | 23 (69.7%) | 25 (64.1%) | 14 (35.9%) | 17 (81.0%) | 4 (19.0%) |
IB** | 59 (22.6%) | 202 (77.4%) | 44 (50.6%) | 43 (49.4%) | 77 (88.5%) | 10 (11.5%) | 56 (100%) | 0 (0%) |
II*** | 213 (56.2%) | 166 (43.8%) | 130 (76.0%) | 41 (24.0%) | 122 (93.1%) | 9 (6.9%) | 75 (100%) | 0 (0%) |
III**** | 68 (81.0%) | 16 (19.0%) | 46 (90.2%) | 5 (9.8%) | 45 (93.8%) | 3 (6.3%) | 13 (100%) | 0 (0%) |
Total | 352 (38.1%) | 571 (61.9%) | 230 (67.3%) | 112 (32.7%) | 269 (88.2%) | 36 (11.8%) | 161 (97.6%) | 4 (2.4%) |